This is a working overview of REV-ERB agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-29 and is reviewed periodically as new material appears.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
medical genetics The branch of medicine and medical science that involves the study, diagnosis, and management of hereditary disorders, and more broadly the application of knowledge about human genetics to medical care.
=== Prehistory === Human remains found in Peștera cu Oase ("Cave with Bones"), radiocarbon date from circa 40,000 years ago, and represent the oldest known Homo sapiens in Europe. Neolithic agriculture spread after the arrival of a mixed group of people from Thessaly in the 6th millennium BC. Excavations at the Poiana Slatinei site near a salt spring next to Lunca, Neamț yielded the earliest evidence for salt exploitation in Europe; here salt production began between the 5th and 4th millennium BC. The first permanent settlements developed into "proto-cities", which were larger than 320 hectares (800 acres). The Cucuteni–Trypillia culture—the best known archaeological culture of Old Europe—flourished in Muntenia, southeastern Transylvania and northeastern Moldavia in the 3rd millennium BC. The first fortified settlements appeared around 1800 BC, showing the militant character of Bronze Age societies.
==== Predation theory for multicellularity ==== This theory postulates that multicellularity arose as a means for prey to escape predation. Larger prey are less likely to be preyed upon, and larger predators are more likely to catch prey. Therefore it is likely that multicellularity arose when the first predators evolved. By assembling as a larger, multicelled organism, prey could escape the attempts of a predator. Therefore multicellularity was selectively favoured over unicellularity. This can be seen in a simple experiment conducted by Boraas et al. (1998). When a predatory protist, Ochromonas valencia, was introduced to a prey population of Chlorella vulgaris, it was seen that within less than 100 generations of the prey species a multicellular growth form of the alga became dominant. This is interesting because before the predator was introduced, the population of Chlorella vulgaris retained its unicellular growth form for thousands of generations. It is likely that it would have remained unicellular indefinitely if the selective pressure that was induced by the predators had not been introduced. After multiple generations with the predator, the algal species retained a growth form of 8-10 cells, which was large enough to avoid the predator, but small enough that each cell still had access to nutrients. This predator-prey relationship provides a likely reason for why it was beneficial for organisms to be multicellular.
Once identified, the leak can often be repaired by an epidural blood patch, an injection of the patient's own blood at the site of the leak, a fibrin glue injection, or surgery. A spontaneous CSF leak is a rare condition, affecting at least one in 20,000 people and many more who go undiagnosed every year. On average, the condition develops at age 42, and women are twice as likely to be affected. Some people with a sCSF leak have a chronic leak despite repeated patching attempts, leading to long-term disability due to pain and being unable to be upright, and surgery is often needed. The symptoms of a spontaneous CSF leak were first described by German neurologist Georg Schaltenbrand in 1938 and by American neurologist Henry Woltman of the Mayo Clinic in the 1950s.
Sources: en.wikipedia.org
=== Academics and Islamic scholars === Muhammad Ibn Muhammad Al-Fulani Al-Kishwani – prominent mathematician in the early 1700s from Katsina Usman dan Fodio (1754–1817) – Islamic scholar, revolutionary from Sokoto, founder and spiritual leader of the Sokoto Caliphate. Abdullahi dan Fodio (1766–1829) – scholar, jurist, pioneer, Grand Vizier of Sokoto and first Emir of Gwandu (r. 1812–1828). Nana Asma'u – princess, poet, Islamic scholar and daughter of Usman dan Fodio. Muhammed Bello (1781–1837) – the first sultan of Sokoto. Abd al-Qadir dan Tafa (1804–1864) – described as the "most learned scholar of his time" in the Sokoto Caliphate who specialized in philosophy (Falsafa) Abu Bakr Atiku (1782–1842) – second sultan of the Sokoto Caliphate, reigning from October 1837 until November 1842. Muhammadu Junaidu – former grand vizier of Sokoto, historian, writer Hayatu ibn Sa'id - great-grandson of Usman dan Fodio, Mahdist leader who attempted to conquer Bornu and The Sokoto Caliphate. Muhammad Bukhari bin Uthman - military commander, scholar and poet. Son Of Usman dan Fodio. Modibbo Adama (1786–1847) – first Laamiɗo and founder of Fombina (Adamawa emirate) which covered parts of Nigeria, Cameroon and Chad. Modibbo Raji – influential 19th century Islamic scholar who is generally regarded as the founder of the Islamic scholarly tradition in Adamawa;Wazir(vizier) in the Gwandu Emirate of the Sokoto Caliphate Muhammad Auwal Albani Zaria - prominent Islamic scholar and reformer. Isa Ali Pantami - Islamic scholar, former Minister of Communications and Digital economy.
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women's health, cancer, and organ health. Natera's proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California and Austin, Texas.
CPA started being used in animal experiments around the world to investigate how antiandrogens affected fetal sexual differentiation. The first clinical use of CPA in the treatment of sexual deviance and prostate cancer occurred in 1966. It was first studied in the treatment of androgen-dependent skin and hair symptoms, specifically acne, hirsutism, seborrhea, and scalp hair loss, in 1969. CPA was first approved for medical use in 1973 in Europe under the brand name Androcur. In 1977, a formulation of CPA was introduced for use by intramuscular injection. CPA was first marketed as a birth control pill in 1978 in combination with ethinylestradiol under the brand name Diane. Following phase III clinical trials, CPA was approved for the treatment of prostate cancer in Germany in 1980. CPA became available in Canada as Androcur in 1987, as Androcur Depot in 1990, and as Diane-35 in 1998. Conversely, CPA was never introduced in any form in the United States. This was reportedly due to concerns about breast tumors observed with high-dose pregnane progestogens in beagle dogs as well as concerns about potential teratogenicity in pregnant women. Use of CPA in transgender women, an off-label indication, was reported as early as 1977. The use of CPA in transgender women was well-established by the early 1990s. The history of CPA, including its discovery, development, and marketing, has been reviewed.
However, the reverse is true in the basic environment of the intestines—weak bases (such as caffeine) will diffuse more readily since they will be non-ionic. This aspect of absorption has been targeted by medicinal chemists. For example, they may choose an analog that is more likely to be in a non-ionic form. Also, the chemists may develop prodrugs of a compound—these chemical variants may be more readily absorbed and then metabolized by the body into the active compound. However, changing the structure of a molecule is less predictable than altering dissolution properties, since changes in chemical structure may affect the pharmacodynamic properties of a drug. The solubility and permeability of a drug candidate are important physicochemical properties the scientist wants to know as early as possible.
24 May – Researchers from the Chinese Academy of Sciences report tuning of the Casimir effect using magnetic fields. 30 May – NASA reports that the James Webb Space Telescope has discovered JADES-GS-z14-0, the most distant known galaxy, which existed only 290 million years after the Big Bang. Its redshift of 14.32 exceeds the previous record of 13.2, set by JADES-GS-z13-0. 31 May – Biologists report that Tmesipteris oblanceolata, a fern ally plant, was found to contain the largest known genome. Promising results of health and medical research are reported: a mRNA vaccine-like immunotherapy against brain cancer tested in a preliminary small trial (1 May), ferrets-tested mRNA vaccine against the clade 2.3.4.4b H5 bird flu amid concerning developments of the 2020–2025 H5N1 outbreak (23 May), mice-tested antibiotic lolamicin specific to Gram-negative bacteria that spares the gut microbiome (29 May).
Sources: en.wikipedia.org
Lead poisoning (Pb), in contrast to arsenic poisoning, is caused by industrial materials, such as leaded gasoline and lead leached from plumbing. Use of leaded gasoline has declined precipitously since the 1970s. Lead (from lead(II) azide or lead styphnate used in firearms) gradually accumulates at firearms training grounds, contaminating the local environment and exposing range employees to a risk of lead poisoning. Beryllium poisoning (Be) is attributed to the ability of Be2+ to replace Mg2+ in some enzymes. Be has been classified by one agency as a carcinogen. Cadmium poisoning (Cd) came into focus with the discovery of itai-itai disease due to cadmium-contaminated waters resulting from mining in the Toyama Prefecture starting around 1912. The term refers to the severe pains (Japanese: 痛い, romanized: itai) people with the condition felt in the spine and joints. Cd2+ is thought to accumulate in the kidneys, where it tightly binds to the sulfur in cysteine-containing proteins. Cadmium is also present as a material used in many electronic devices, thus it can leach into groundwater after being disposed of into landfills of electronic waste. Chromium poisoning (Cr) is primarily due to hexavalent chromium, Cr+6, creating as a side effect of industrial processes. While hexavalent chromium is a known human carcinogen, and it has become widespread in the environment, the impact of environmental contamination with this element are not known. Mercury poisoning (Hg) came into sharp focus with the discovery of Minamata disease, named for the Japanese city of Minamata.
However, several species of bacteria are pathogenic and cause infectious diseases, including cholera, syphilis, anthrax, leprosy, tuberculosis, tetanus and bubonic plague. The most common fatal bacterial diseases are respiratory infections. Antibiotics are used to treat bacterial infections and are also used in farming, making antibiotic resistance a growing problem. Bacteria are important in sewage treatment and the breakdown of oil spills, the production of cheese and yogurt through fermentation, the recovery of gold, palladium, copper and other metals in the mining sector (biomining, bioleaching), as well as in biotechnology, and the manufacture of antibiotics and other chemicals. Once regarded as plants constituting the class Schizomycetes ("fission fungi"), bacteria are now classified as prokaryotes. Unlike cells of animals and other eukaryotes, bacterial cells contain circular chromosomes, do not contain a nucleus and rarely harbour membrane-bound organelles. Although the term bacteria traditionally included all prokaryotes, the scientific classification changed after the discovery in the 1990s that prokaryotes consist of two very different groups of organisms that evolved from an ancient common ancestor. These evolutionary domains are called Bacteria and Archaea. Unlike Archaea, bacteria contain ester-linked lipids in the cell membrane, possess elongation factors that are resistant to ADP-ribosylation by diphtheria toxin, use formylmethionine in protein synthesis initiation, and have numerous genetic differences, including a different 16S rRNA.
=== Criminal use === In late August 2018, a South Carolina woman was charged with murdering her husband by putting eye drops containing tetryzoline in his drinking water. An autopsy found a high concentration of tetryzoline in his body. Tetryzoline has been used as a date rape drug in a number of cases because of its ability to cause dizziness and unconsciousness. In 2018, a 62 year-old woman in Pewaukee, Wisconsin, died in an apparent overdose or suicide involving tetryzoline and other substances; in November 2023 her caregiver was convicted of first-degree murder, following the allegation that her death was caused by a water bottle laced with Visine. In 2019, a North Carolina paramedic was accused of using tetryzoline eye drops to cause the death of his wife. The blood sample results showed about 30–40 times higher than the therapeutic level of tetryzoline.
Proteins are often thought of as relatively stable tertiary structures that experience conformational changes after being affected by interactions with other proteins or as a part of enzymatic activity. However, proteins may have varying degrees of stability, and some of the less stable variants are intrinsically disordered proteins. These proteins exist and function in a relatively 'disordered' state lacking a stable tertiary structure. As a result, they are difficult to describe by a single fixed tertiary structure. Conformational ensembles have been devised as a way to provide a more accurate and 'dynamic' representation of the conformational state of intrinsically disordered proteins. Protein ensemble files are a representation of a protein that can be considered to have a flexible structure. Creating these files requires determining which of the various theoretically possible protein conformations actually exist. One approach is to apply computational algorithms to the protein data in order to try to determine the most likely set of conformations for an ensemble file. There are multiple methods for preparing data for the Protein Ensemble Database that fall into two general methodologies – pool and molecular dynamics (MD) approaches (diagrammed in the figure). The pool based approach uses the protein's amino acid sequence to create a massive pool of random conformations. This pool is then subjected to more computational processing that creates a set of theoretical parameters for each conformation based on the structure.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.